Multispecific antigen-binding molecules that bind PSMA and 4-1BB and methods of use thereof

TW202641836APending Publication Date: 2026-10-16REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114141854
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-30
Filing Date
2025-10-29
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080573_001
    Figure TWG2TA001080573_001
  • Figure TWG2TA001080573_002
    Figure TWG2TA001080573_002
  • Figure TWG2TA001080573_003
    Figure TWG2TA001080573_003
Patent Text Reader

Abstract

The present disclosure provides multispecific antigen-binding molecules that bind to prostate specific membrane antigen (PSMA) and 4-1BB (anti-PSMA x anti-4-1BB). In certain embodiments, the present disclosure provides a multispecific anti-PSMA x anti-4-1BB antigen-binding molecule or antigen-binding fragment thereof comprising a first antigen-binding domain that specifically binds PSMA, a second antigen-binding domain that specifically binds 4-1BB, and a third antigen-binding domain that specifically binds 4-1BB. In certain embodiments, the molecules are multispecific antibodies or antigen-binding fragments thereof. In certain embodiments, the multispecific antibodies disclosed herein bind PSMA expressed on tumor cells with the first antigen-binding domain and 4-1BB on immune cells (e.g., T cells) with the second and third antigen-binding domains. In certain embodiments, the antibodies of the present disclosure are useful in treatment of a cancer. In certain embodiments, the antibodies are useful for treating a PSMA-associated disease or disorder (e.g., prostate cancer).
Need to check novelty before this filing date? Find Prior Art